Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Alexander GG Turpie
Department of Medicine, McMaster University, Hamilton, ONT, Canada

Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke, accounting for up to 15% of strokes in the general population. The European Society of Cardiology now recommends direct oral anticoagulants, such as rivaroxaban, apixaban, and dabigatran, in preference to vitamin K antagonist therapy for the prevention of stroke in patients with AF. This review focuses on the direct Factor Xa inhibitor rivaroxaban, summarizing the properties that make rivaroxaban appropriate for anticoagulant therapy in this indication (including its predictable pharmacokinetic and pharmacodynamic profile and once-daily dosing regimen) and describing data from the Phase III ROCKET AF trial, which showed once-daily rivaroxaban to be noninferior to warfarin for the prevention of stroke in patients with nonvalvular AF. In this trial, similar rates of major and nonmajor clinically relevant bleeding were observed; however, when compared with warfarin, rivaroxaban was associated with clinically significant reductions in intracranial and fatal bleeding. On the basis of these results, rivaroxaban was approved in both the United States and the European Union for the prevention of stroke and systemic embolism in patients with nonvalvular AF. Subanalyses of ROCKET AF data showed rivaroxaban to have consistent efficacy and safety across a wide range of patients, and studies to confirm these results in real-world settings are underway. This review also describes practical considerations for treatment with rivaroxaban in clinical practice (including dose reductions in specific high-risk patients, eg, those with renal impairment), recommendations for the transition from vitamin K antagonists to rivaroxaban, the management of bleeding events, and the measurement of rivaroxaban exposure.

Keywords: atrial fibrillation, stroke, rivaroxaban, anticoagulation

Introduction
In the past 5 years, the oral, direct Factor Xa inhibitor rivaroxaban has been approved in five different thromboembolic indications for seven different areas of use (listed in Table 1). The indication on which this article focuses is the reduction of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), for which rivaroxaban has been approved in the United States (US) and the European Union (EU) at a dose of 20 mg once daily (15 mg once daily in patients with creatinine clearance [CrCl] 15–50 mL/minute and 15–49 mL/minute in the US and EU, respectively).

AF is the most common cardiac arrhythmia and is a major risk factor for stroke and systemic embolism. The prevalence of AF in the general population of the developed world is 1.5%–2.0%; in the US alone, more than 2 million people are affected by this condition. Adults aged 40 years or older have a one in four risk for developing AF; the
Table 1 Dosing regimens of rivaroxaban in adult patients for approved indications in the European Union and the US

<table>
<thead>
<tr>
<th>Approved indications</th>
<th>European Union</th>
<th>US</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of stroke and systemic embolism in patients with nonvalvular AF</td>
<td>20 mg od (15 mg od in patients with CrCl 15–49 mL/minute)</td>
<td>20 mg od (15 mg od in patients with CrCl 15–50 mL/minute)</td>
</tr>
<tr>
<td>VTE prevention after elective hip or knee replacement surgery</td>
<td>10 mg od</td>
<td>10 mg od</td>
</tr>
<tr>
<td>Treatment of DVT or PE</td>
<td>15 mg bid for 3 weeks</td>
<td>15 mg bid for 3 weeks</td>
</tr>
<tr>
<td>Prevenion of recurrent DVT and PE</td>
<td>20 mg od thereafer</td>
<td>20 mg od thereafer</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with ACS with elevated cardiac biomarkers†</td>
<td>2.5 mg bid</td>
<td>Not approved</td>
</tr>
</tbody>
</table>

Note: †Rivaroxaban is coadministered with acetylsalicylic acid alone or with acetylsalicylic acid plus clopidogrel or ticlopidine. Data from references 2 and 3. Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; bid, twice daily; CrCl, creatinine clearance; DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; US, United States; VTE, venous thromboembolism.

average age of patients with AF is 75–85 years, and the prevalence of AF is approximately 10% in patients aged 85 years and older.5–7 Compared with the general population, patients with AF have a fivefold increase in the risk of stroke.5 Moreover, AF is associated with a threefold increase in the incidence of congestive heart failure,6 a risk that is even higher in patients older than 80 years of age.6 In patients with AF, stroke is associated with a poorer prognosis, an increased rate of medical and neurological complications, and a higher in-hospital mortality than it is in patients without AF.9 After an AF-related stroke, almost 50% of patients die within 1 year;10 furthermore, among patients with AF who were admitted to the hospital with a first ischemic stroke, 60% of strokes were disabling and 20% of strokes were fatal.11 Owing to the substantial increase in the risk of stroke in patients with AF, anticoagulants that target multiple components in the coagulation cascade, such as the vitamin K antagonist (VKA) warfarin, have become the mainstay of therapy for stroke prevention in patients with nonvalvular AF.8,11 However, warfarin is associated with many limitations, including the need for regular coagulation monitoring. The effects of warfarin are influenced by numerous food and drug interactions as well as by genetic variations, which can result in an unpredictable response.13,14 This has prompted the development of target-specific oral anticoagulants, including the Factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and the thrombin inhibitor dabigatran etexilate.

The objective of this review is to provide an overview of the pharmacological characteristics of rivaroxaban and its practical implementation as a once-daily oral anticoagulant with minimal drug–drug interactions and without a need for routine coagulation monitoring for stroke prevention in patients with nonvalvular AF.

Guidelines for stroke prevention in atrial fibrillation

Current guidelines for the management of patients with AF recommend long-term oral anticoagulant therapy based on respective stroke risk.6,15

Recommendations from the European Society of Cardiology (ESC)6 are based on the CHA2DS2-VASc scoring system (congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years [2 points], diabetes, stroke [2 points], vascular disease, age 65–74 years, sex category [female]), which is more sensitive for the detection of truly low-risk patients with AF than is the more widely used CHADS2 scoring system (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack [TIA; 2 points]). According to the ESC guidelines, the use of oral anticoagulation therapy with rivaroxaban, dabigatran, or apixaban is recommended in preference to the use of a VKA in patients with nonvalvular AF and a CHA2DS2-VASc score ≥2. In patients with a CHA2DS2-VASc score of 1, oral anticoagulation therapy should be considered on the basis of risk for bleeding complications and patient preference, but no therapy should be considered if the score of 0 or 1 is based on female sex. The ESC recommends using antiplatelet therapy (with acetylsalicylic acid [ASA] plus clopidogrel or ASA alone) only in patients who refuse or cannot tolerate oral anticoagulants for reasons other than bleeding.6

Guidelines from the American College of Chest Physicians15 are based on risk stratification of patients according to the CHADS2 scoring system. These guidelines recommend anticoagulation with dabigatran or warfarin in patients with a CHADS2 score of ≥2 and consider rivaroxaban and apixaban as reasonable alternatives. In patients who are not suitable for oral anticoagulation, ASA plus clopidogrel may be considered. Individualized treatment approaches are recommended for patients with a CHADS2 score <2.15
Rivaroxaban: a once-daily oral anticoagulant

Rivaroxaban directly inhibits both free and clot-bound Factor Xa and prevents the formation of new clots and the extension of existing clots. Rivaroxaban is absorbed rapidly from the gastrointestinal tract and reaches peak plasma concentrations within 2–4 hours. Maximum inhibition of Factor Xa activity, prolongation of prothrombin time (PT; with a sensitive thromboplastin reagent), and prolongation of activated partial thromboplastin time (which is less predictable) all occur approximately 2–3 hours after dosing; however, measurements can vary depending on the reagents used. Rivaroxaban has a half-life of 5–9 hours in healthy subjects and 11–13 hours in elderly patients. Furthermore, rivaroxaban has predictable pharmacokinetics and pharmacodynamics and minimal food and drug interactions. Importantly, rivaroxaban has a dual mode of elimination: one-third is eliminated as unchanged drug in the urine; two-thirds undergoes metabolic degradation in the liver, half of which is excreted via the kidneys and half via the hepatobiliary route. High oral bioavailability (80%–100%) of rivaroxaban (at doses of 2.5 mg and 10.0 mg) is achieved irrespective of fasting or fed conditions, and this high bioavailability continues up to a dose of 15.0 mg. Bioavailability and absorption decrease at higher doses of rivaroxaban; however, this decrease is less pronounced if the dose is taken with food.

Patients with AF are frequently elderly and have one or more comorbidities requiring additional medications. Rivaroxaban is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, in patients with clinically significant active bleeding, and in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with moderate or severe hepatic impairment (classified as Child–Pugh B or C). Furthermore, rivaroxaban is contraindicated in women who are pregnant or breastfeeding. Rivaroxaban is absorbed rapidly from the gastrointestinal tract and reaches peak plasma concentrations within 2–4 hours. Maximum inhibition of Factor Xa activity, prolongation of prothrombin time (PT; with a sensitive thromboplastin reagent), and prolongation of activated partial thromboplastin time (which is less predictable) all occur approximately 2–3 hours after dosing; however, measurements can vary depending on the reagents used. Rivaroxaban has a half-life of 5–9 hours in healthy subjects and 11–13 hours in elderly patients. Furthermore, rivaroxaban has predictable pharmacokinetics and pharmacodynamics and minimal food and drug interactions. Importantly, rivaroxaban has a dual mode of elimination: one-third is eliminated as unchanged drug in the urine; two-thirds undergoes metabolic degradation in the liver, half of which is excreted via the kidneys and half via the hepatobiliary route. High oral bioavailability (80%–100%) of rivaroxaban (at doses of 2.5 mg and 10.0 mg) is achieved irrespective of fasting or fed conditions, and this high bioavailability continues up to a dose of 15.0 mg. Bioavailability and absorption decrease at higher doses of rivaroxaban; however, this decrease is less pronounced if the dose is taken with food.

Rivaroxaban in atrial fibrillation: the ROCKET AF trial

ROCKET AF was a large, international, randomized, double-blind, event-driven Phase III study of 14,264 patients with nonvalvular AF, comparing once-daily rivaroxaban with dose-adjusted warfarin. Patients were randomized to receive either rivaroxaban 20 mg once daily (or 15 mg once daily in patients with CrCl 30–49 mL/minute at screening) or dose-adjusted warfarin (international normalized ratio [INR] 2.0–3.0). In this study, the median patient age was 73 years, and 39.7% of patients were women. The mean CHADS2 score was 3.5 and more than 86.9% of patients had a CHADS2 score of ≥3. The median CrCl was 67 mL/minute. Prior to enrollment in ROCKET AF, 62.4% of patients had been treated with a VKA. The patients had high rates of coexisting conditions, including previous stroke, systemic embolism, or TIA (54.8%), previous heart failure (62.5%), hypertension (90.5%), and diabetes (40.0%).

The primary efficacy endpoint was the composite of stroke (ischemic or hemorrhagic) and systemic embolism. In the primary efficacy analysis of the per-protocol as-treated population, this endpoint occurred at a rate of 1.7%/year in the rivaroxaban arm and 2.2%/year in the warfarin arm (hazard ratio [HR]=0.79; 95% confidence interval [CI]=0.66%–0.96%; P<0.001 for noninferiority). In the as-treated safety population, rivaroxaban demonstrated superior efficacy, with primary endpoints occurring at a rate of 1.7%/year and 2.2%/year in the rivaroxaban and warfarin arms, respectively (HR=0.79; 95% CI =0.65%–0.95%; P=0.02 for superiority). In the intent-to-treat
population, rivaroxaban was noninferior to warfarin for the primary efficacy endpoint \( (HR = 0.88; 95\% CI = 0.75\%–1.03\%); P < 0.001 for noninferiority). The event rates of all-cause deaths and myocardial infarction were lower in the rivaroxaban group than in the warfarin group; however, these reductions were not statistically significant. The principal safety endpoint of major and nonmajor clinically relevant bleeding was similar in both treatment groups, occurring at a rate of 14.9\%/year in patients receiving rivaroxaban and at 14.5\%/year in patients receiving warfarin \( (P = 0.44) \) (Table 3). Rates of any major bleeding events were also similar in both treatment groups (3.6\% in the rivaroxaban group and 3.4\% in the warfarin group; \( P = 0.58 \)). Rivaroxaban was associated with significant reductions in the rates of intracranial hemorrhage (ICH; 0.5\% versus 0.7\%; \( P = 0.02 \)) and fatal bleeding (0.2\% versus 0.5\%; \( P = 0.003 \)) when compared with warfarin.\(^4\) Major bleeding from a gastrointestinal site (3.2\% versus 2.2\%; \( P < 0.001 \)) and the need for transfusion (2.6\% versus 2.1\%; \( P = 0.04 \)) were more common in the rivaroxaban group than the warfarin group.

The dosing regimen for ROCKET AF (20 mg once daily; 15 mg once daily in patients with CrCl 30–49 mL/minute) was based on Phase II dose-finding studies in patients treated for acute deep vein thrombosis and on exposure simulations in patients with AF.\(^23,24,28\) The simulations in virtual patient populations with AF showed that a rivaroxaban dose of 15 mg once daily in patients with CrCl 30–49 mL/minute would achieve exposure similar to that observed with 20 mg once daily in patients with normal renal function.\(^23\) In summary, rivaroxaban can be administered orally as a fixed once-daily dose and without routine coagulation monitoring; dose adjustment is only required in the treatment of AF patients with moderate-to-severe renal impairment.\(^23\) The Phase III ROCKET AF trial successfully tested and validated the reduced dose of 15 mg once daily for patients with renal impairment (CrCl 30–49 mL/minute), resulting in the subsequent approval of this dose.\(^4\) When analyzing outcomes of ROCKET AF according to patient age or CHADS\(_2\) score, rivaroxaban demonstrated consistent noninferior efficacy and a similar safety profile compared with warfarin.\(^4,29\) Furthermore, prespecified subgroup analyses compared the efficacy and safety outcomes in patients with moderate renal impairment (CrCl 30–49 mL/minute; rivaroxaban group receiving 15 mg once daily) with those in patients with normal renal function (rivaroxaban group receiving 20 mg once daily),\(^26\) in

| Table 2 Dosing regimens of apixaban, dabigatran, and rivaroxaban for the prevention of stroke in patients with AF in the European Union and US |
|-----------------|-----------------|-----------------|
| **European Union** | **US** |
| **Recommended dose** | **Recommended dose** | **Recommended dose** |
| Rivaroxaban | Dabigatran | Apixaban |
| 5 mg bid in patients with CrCl $\geq$ 30 mL/minute | 5 mg bid in patients with CrCl $\geq$ 15 mL/minute | 20 mg od in patients with CrCl $\geq$ 50 mL/minute |
| Dose adjustments | 2.5 mg bid in the presence of $\geq$ 2 of the following characteristics: | 150 mg bid in patients with CrCl $\geq$ 30 mL/minute (unless concomitantly using P-gp inhibitors; see dose adjustments) |
| Age $\geq$ 80 years | Body weight $\geq$ 60 kg | 150 mg bid if CrCl $\geq$ 50 mL/minute |
| Serum creatinine $\geq$ 1.5 mg/dL (133 $\mu$mol/L) | 110 mg bid may be considered in patients with the following factors: | 15 mg od if CrCl $\geq$ 49 mL/minute |
| Age $\geq$ 80 years (or 75–80 years with high risk of bleeding) | Serum creatinine $\geq$ 1.5 mg/dL (133 $\mu$mol/L) | 15–49 mL/minute |
| Serum creatinine $\geq$ 1.5 mg/dL (133 $\mu$mol/L) with a high risk of bleeding | 15–50 mL/minute | 15 mg od if CrCl $\geq$ 50 mL/minute |
| Contraindicated in patients with CrCl $\leq$ 15 mL/minute | Avoid use in patients with CrCl $\leq$ 15 mL/minute | 15–50 mL/minute |
| No contraindications but not recommended in patients with CrCl $< 15$ mL/minute | No contraindications but not recommended in patients with CrCl $< 15$ mL/minute | $< 15$ mL/minute |

**Note:** Data from references 2, 3, and 51–54.

**Abbreviations:** AF, atrial fibrillation; bid, twice daily; CrCl, creatinine clearance; od, once daily; P-gp, P-glycoprotein; US, United States.
Table 3 Summary of efficacy and safety results in ROCKET AF and in subgroup analyses (event rate per 100 patient-years of follow-up; percentage of events per year)

<table>
<thead>
<tr>
<th>Study</th>
<th>Primary efficacy endpoint</th>
<th>Warfarin</th>
<th>Rivaroxaban</th>
<th>HR (95% CI)</th>
<th>P-value</th>
<th>Principal safety endpoint</th>
<th>Warfarin</th>
<th>Rivaroxaban</th>
<th>HR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROCKET AF: per-protocol, as-treated study population for primary efficacy endpoint; safety, as-treated population for principal safety endpoint</td>
<td>Overall</td>
<td>1.7</td>
<td>2.2</td>
<td>0.79 (0.66–0.96)</td>
<td>&lt;0.001 (for noninferiority)</td>
<td>14.9</td>
<td>14.5</td>
<td>1.03 (0.96–1.11)</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Renal function subgroups: per-protocol, as-treated study population for primary efficacy endpoint; safety, as-treated population for principal safety endpoint</td>
<td>CrCl 30–49 mL/minute</td>
<td>2.32</td>
<td>2.77</td>
<td>0.84 (0.57–1.23)</td>
<td>0.76</td>
<td>17.82</td>
<td>18.28</td>
<td>0.98 (0.84–1.14)</td>
<td>0.4496</td>
<td></td>
</tr>
<tr>
<td>CrCl ≥50 mL/minute</td>
<td>1.57</td>
<td>2.00</td>
<td>0.78 (0.63–0.98)</td>
<td>14.24</td>
<td>13.67</td>
<td>1.04 (0.96–1.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of previous stroke or TIA: intent-to-treat population for primary efficacy endpoint; safety, as-treated population for principal safety endpoint</td>
<td>No</td>
<td>1.44</td>
<td>1.88</td>
<td>0.77 (0.58–1.01)</td>
<td>0.23</td>
<td>16.69</td>
<td>15.19</td>
<td>1.10 (0.99–1.21)</td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2.79</td>
<td>2.96</td>
<td>0.94 (0.77–1.16)</td>
<td>13.31</td>
<td>13.87</td>
<td>0.96 (0.87–1.07)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VKA-naive or VKA-experienced patients: intent-to-treat population for primary efficacy endpoint; safety, as-treated population for principal safety endpoint</td>
<td>VKA-naive</td>
<td>2.32</td>
<td>2.87</td>
<td>0.81 (0.64–1.03)</td>
<td>0.36</td>
<td>11.20</td>
<td>12.87</td>
<td>0.84 (0.74–0.95)</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>VKA-experienced</td>
<td>1.98</td>
<td>2.09</td>
<td>0.94 (0.75–1.18)</td>
<td>14.73</td>
<td>14.28</td>
<td>1.06 (0.96–1.17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with or without HF: intent-to-treat population for primary efficacy endpoint; safety, as-treated population for principal safety endpoint</td>
<td>With HF</td>
<td>1.90</td>
<td>2.09</td>
<td>0.91 (0.74–1.13)</td>
<td>0.62</td>
<td>14.22</td>
<td>14.02</td>
<td>1.05 (0.95–1.15)</td>
<td>0.99</td>
<td></td>
</tr>
<tr>
<td>Without HF</td>
<td>2.10</td>
<td>2.54</td>
<td>0.84 (0.65–1.09)</td>
<td>16.12</td>
<td>15.35</td>
<td>1.05 (0.93–1.18)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Abbreviations: CI, confidence interval; CrCl, creatinine clearance; HF, heart failure; HR, hazard ratio; od, once daily; TIA, transient ischemic attack; VKA, vitamin K antagonist.

patients with and without previous stroke or TIA,²⁷ in patients with and without heart failure and AF,³⁰ and in VKA-naive and VKA-experienced patients.³¹ These analyses showed no differences in efficacy outcomes when both treatment arms were compared and showed similar or lower rates of bleeding with rivaroxaban, thereby confirming the overall results of ROCKET AF and supporting the use of rivaroxaban as an alternative treatment option to warfarin for the prevention of stroke and systemic embolism in these subgroups of patients with AF (Table 3). In addition, the results of one study, which provided a benefit–risk assessment of the effect of reduced-dose rivaroxaban compared with warfarin (in patients with moderate renal insufficiency), demonstrated that patients with renal impairment have a higher risk of stroke and systemic embolism than patients with normal renal function, independent of the anticoagulant administered.²⁶

A post hoc analysis of patients with AF who were enrolled in ROCKET AF demonstrated that, while on treatment, patients with prior myocardial infarction receiving rivaroxaban had fewer ischemic cardiac events than those receiving warfarin.³²

At the end of the study period of ROCKET AF, participating sites were notified and patients in the intent-to-treat population were switched to open-label conventional anticoagulants. As per study design, patients on warfarin continued to receive the drug whereas patients in the rivaroxaban group discontinued rivaroxaban and started warfarin therapy, resulting in a period of inadequate anticoagulation in these patients. This transitioning protocol explains differences between treatment groups in the median times to reach therapeutic INR, namely 13 days for patients in the rivaroxaban group compared with 3 days for patients in the warfarin group. Patients in the rivaroxaban group had a significantly higher event rate during the end-of-study transition period (day 2 to day 30 after study end) compared with patients in the warfarin group (22 versus 7; P=0.008).

A separate prospective, randomized, double-blind, Phase III safety trial in 1,280 Japanese patients with AF and a moderate-to-high risk of stroke (mean CHADS² score 3.25), J-ROCKET AF compared the safety of rivaroxaban 15 mg once daily (10 mg once daily for patients with CrCl 30–49 mL/minute) with dose-adjusted warfarin according to Japanese guidelines (target INR of 2.0–3.0 in patients aged <70 years; a reduced target INR of 1.6–2.6 in patients aged ≥70 years).³³ This study demonstrated the noninferiority of rivaroxaban to warfarin for the principal safety outcome of major and nonmajor clinically relevant bleeding.
in the on-treatment safety population (18.04%/year versus 16.42%/year; HR = 1.11; 95% CI = 0.87%–1.42%; P < 0.001). There was a strong trend for a reduction in the rate of the primary efficacy endpoint in the per-protocol as-treated population (defined as the composite of stroke and systemic embolism) with rivaroxaban versus warfarin (HR = 0.49; P = 0.050). Rates of ICH were lower in the rivaroxaban group than the warfarin group (0.8%/year versus 1.6%/year). Similarly, the rate of the composite secondary efficacy endpoint of stroke, non-central-nervous-system systemic embolism, and vascular death was lower in the rivaroxaban group than the warfarin group (1.8%/year versus 2.9%/year; HR = 0.65; 95% CI = 0.34%–1.22%).

Real-world experience
Clinical trial criteria do not always reflect real-world settings because they select patients according to strict inclusion/exclusion criteria and prespecify the active comparator and treatment approach, including duration, intervention, and outcome measures. Phase IV nonintervention studies have an important role in assessing the efficacy and safety of newly approved drugs in routine clinical practice.

The aim of the ongoing nonintervention XANTUS study is to evaluate the effectiveness of rivaroxaban for the prevention of stroke and non-central-nervous-system systemic embolism in patients with nonvalvular AF in real-world clinical practice, with an estimated enrollment of 6,000 patients. Additional real-world studies are underway.

Practical considerations
There are a number of practical aspects to take into account when considering rivaroxaban therapy for the prevention of stroke and systemic embolism in patients with nonvalvular AF. The necessity for dose reductions in patients with renal impairment has already been covered in detail. Some clinical scenarios, such as surgical interventions or invasive procedures, may require patients to delay the next rivaroxaban dose to minimize risk of bleeding. Where possible, interventions should be carried out at trough rivaroxaban plasma concentrations and avoided at peak rivaroxaban plasma concentrations. After the intervention, rivaroxaban should be restarted as soon as possible to minimize time without anticoagulation. In cases in which there are problems with adherence to or compatibility with a VKA, it may be advantageous to switch patients to rivaroxaban. In ROCKET AF, the higher event rate when switching patients from rivaroxaban to warfarin during the end-of-study transition period highlights the importance of carefully monitoring the anticoagulation status of individual patients to ensure adequate anticoagulation during transition.

Recommendations for switching strategies were recently published. In summary, when transitioning patients from rivaroxaban to VKAs, VKA therapy should be initiated while patients continue on rivaroxaban and until the INR is ≥ 2.0, at which point rivaroxaban can be discontinued. When transitioning from a VKA to rivaroxaban, once the INR is ≥ 3.0 after stopping VKA, rivaroxaban can be initiated at the recommended dose. Pharmacokinetic properties of the specific VKA must be considered during transition, in addition to the bleeding risk of the patient.

Other aspects, such as the optimal timing of initiating therapy after a stroke or ICH, are currently unresolved. Standard procedures are in place for the management of minor to moderate bleeding events. In rare cases of severe, life-threatening bleeding events, the use of a reversal agent may be beneficial. Reversal agents, such as prothrombin complex concentrate, activated prothrombin complex concentrate, and recombinant Factor VIIa, have been evaluated principally for their potential to reverse the anticoagulant activity of rivaroxaban in ex vivo or animal studies. Data from studies in healthy volunteers are also available. Additionally, a recombinant form of Factor Xa, the r-Antidote andexanet alfa (PRT064445; Portola Pharmaceuticals Inc., South San Francisco, CA, USA), which is catalytically inactive but retains its ability to bind direct Factor Xa inhibitors, has been evaluated as a reversal agent for the new oral anticoagulants. This study demonstrated that r-Antidote has the potential to neutralize rivaroxaban, betrixaban, and apixaban in animal models. Clinical trials are currently underway to evaluate the reversal potential of agents for several anticoagulants in vivo and in patients with life-threatening bleeding.

Rivaroxaban does not require routine coagulation monitoring but some clinical situations may require measurement of rivaroxaban exposure, eg, in patients with suspected overdose or if noncompliance is suspected, in patients who require emergency surgery, or in patients with a thromboembolic or hemorrhagic event. Routine coagulation assays, such as PT and activated partial thromboplastin time, are not suitable for the quantitative assessment of rivaroxaban exposure because they do not reflect plasma levels of rivaroxaban. Importantly, owing to their different response sensitivities to rivaroxaban, different PT reagents will yield markedly varied PT results. PT assays that predominantly use Neoplastin Plus (Roche Diagnostics, Mannheim, Germany) provide a qualitative measurement, whereas anti-Factor Xa chromogenic assays measure rivaroxaban concentrations quantitatively. Both of these laboratory assays have
a number of advantages and disadvantages (Table 4) but, importantly, have been shown to provide reliable results. Anti-Factor Xa chromogenic-specific and highly sensitive assays are recommended when quantitative measurements of rivaroxaban exposure are needed. PT is recommended when anti-Factor Xa chromogenic assays are not available and a qualitative measure or rivaroxaban exposure is required.19

### Conclusion

AF remains a significant healthcare burden that is expected to increase as the population of the developed world ages. There is a need for effective and convenient oral anticoagulation without requiring routine coagulation monitoring, dose adjustments, or dietary restrictions. Rivaroxaban offers such a treatment option and is indicated in the US and the EU for the prevention of stroke and systemic embolism in patients with nonvalvular AF.1,2 The results of the Phase III ROCKET AF study demonstrated that rivaroxaban (20 mg once daily, or 15 mg once daily for patients with CrCl 30–49 mL/minute) was noninferior (compared with warfarin) for the prevention of stroke and systemic embolism in patients with nonvalvular AF and a moderate-to-high risk of stroke. Rates of major and nonmajor clinically relevant bleeding were similar in both treatment groups, but there were significantly fewer ICHs and fatal bleeding events in the rivaroxaban group than in the warfarin group. Analyses in patient subgroups – including patients with moderate renal impairment, elderly patients (≥75 years), patients with prior myocardial infarction, and patients with prior stroke or TIA – confirmed the overall results of ROCKET AF, demonstrating that rivaroxaban is a valid alternative to warfarin for the reduction of stroke and systemic embolism across a wide range of patients with AF. Despite clear guidance on the use of rivaroxaban for stroke prevention in patients with nonvalvular AF, certain questions, such as the optimal timing of initiation of therapy after stroke, remain unanswered. The large, international GARFIELD (Global Anticoagulant Registry in the FIELD) registry, which collects real-life management and outcomes of patients newly diagnosed with nonvalvular AF, may provide valuable insight into best practices and treatment options for specific patient subgroups.

### Acknowledgments

The author would like to acknowledge Isabel Ruthven and Claudia Wiedemann, who provided editorial support with funding from Bayer HealthCare Pharmaceuticals and Janssen Research and Development, LLC.

### Disclosure

Dr Turpie has been a consultant to Bayer HealthCare, Janssen Research and Development, LLC, Astellas Pharma, Portola Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. The author reports no other conflicts of interest in this work.

### References


<table>
<thead>
<tr>
<th>Assay</th>
<th>Recommendations</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Factor Xa chromogenic</td>
<td>• This assay is recommended (over PT measurement) and</td>
<td>• Specific and sensitive quantitative measure</td>
<td>• Requires rivaroxaban calibrators and controls</td>
</tr>
<tr>
<td>assay</td>
<td>should always be used if possible</td>
<td>• Determines plasma levels after all approved therapeutic doses of</td>
<td>• Assay is not available in many hospitals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rivaroxaban have been administered</td>
<td>• Results need to be interpreted in relation to the timing of the tablet intake, in accordance with the pharmacokinetic profile</td>
</tr>
<tr>
<td>Prothrombin time</td>
<td>• Measurement of PT with a reagent sensitive to</td>
<td>• Assay is widely available</td>
<td>• Gives a qualitative assessment expressed in seconds</td>
</tr>
<tr>
<td></td>
<td>rivaroxaban (such as Neoplastin Plus; Roche</td>
<td>• Simple assay</td>
<td>• Notable variations with different reagents</td>
</tr>
<tr>
<td></td>
<td>Diagnostics, Mannheim, Germany) may be used for</td>
<td>• Quick results</td>
<td>• Conventional INR must not be used because INR does not correct for</td>
</tr>
<tr>
<td></td>
<td>qualitative assessment only (measured in seconds)</td>
<td></td>
<td>variations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The use of PT/INR or CoaguCheck tests (Roche Diagnostics, Mannheim, Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>or PT with insensitive reagents (such as Innovin® [Siemens HealthCare Diagnostic Products GmBH, Marburg, Germany]) is not recommended</td>
</tr>
</tbody>
</table>

**Note:** Data from references 2, 19, 49, and 55.

**Abbreviations:** INR, international normalized ratio; PT, prothrombin time.


